Business Context and Reporting Period
Company: CytoSorbents Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: November 4, 2015
Event: Entry into a Material Definitive Agreement (Controlled Equity Offering Sales Agreement).
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It details a financing arrangement with the following parameters:
- Maximum Offering Size: Up to $25,000,000 in aggregate offering price.
- Agent: Cantor Fitzgerald & Co.
- Commission Rate: 3.0% of aggregate gross proceeds.
- Expense Reimbursement Cap: Up to $50,000 for specified expenses.
Material Changes
The Company entered into a Sales Agreement on November 4, 2015, authorizing an "at-the-market" offering of common stock. This agreement allows the Company to sell shares from time to time through Cantor Fitzgerald on the NASDAQ Capital Market or via privately negotiated transactions. The Company retains the right to set minimum sales prices and instruct the agent to halt sales.
Guidance, Outlook, and Use of Proceeds
Management intends to use net proceeds from the offering for the following purposes:
- Research and development activities, including funding additional clinical studies.
- Costs of obtaining regulatory approvals in countries not covered by the CE Mark.
- Capital expenditures and costs to expand production capacity.
- Sales and marketing efforts.
- Product development and general working capital.
Risks/Contingencies: The Company is not obligated to sell any shares. The offering will terminate upon the sale of all shares or earlier termination by either party. No sales will occur in jurisdictions where such offers are unlawful prior to registration.
Investor Verification Checklist
- Verify the status of the shelf registration statement (Form S-3, No. 333-205806) declared effective on July 29, 2015.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific termination rights and pricing mechanisms.
- Monitor future filings for actual share sales and proceeds raised under this agreement.
- Confirm the Company's current cash position to assess the necessity of this capital raise for ongoing clinical trials.